1. Sharpe R.M., Skakkebaek N.E. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 1993;341:1392–5.
2. Garner M.J., Turner M.C., Ghadirian P., Krewski D. Epidemiology of testicular cancer: an overview. Int J Cancer 2005;116:331–9.
3. Chieffi P., Franco R., Portella G. Molecular and cell biology of testicular germ cell tumors. Int Rev Cell Mol Biol 2009;278:277–308.
4. Hemminki K., Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl 2006;29(1):205–10.
5. Looijenga L.H., de Munnik H., Oosterhuis J.W. A molecular model for the development of germ cell cancer. Int J Cancer 1999;83:809–14.
6. Grigor K.M., Skakkebaek N.E. Pathogenesis and cell biology of germ cell neoplasia: general discussion. Eur Urol 1993;23:46–53.
7. Ferlay J., Colombet M., Soerjomataram I. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356–87.
8. WHO classification of tumours of the urinary system and male genital organs. Ed. by H. Moch et al. Lyon: IARC, 2016.
9. Testis. In: TNM classification of malignant tumours (8th ed.). Ed. by J.D. Brierley, M.K. Gospodarowicz, C. Wittekind. Oxford: Wiley-Blackwell, 2017.
10. International Germ Cell Consensus сlassification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594–603.
11. Oldenburg J., Fosså S. D., Nuver J. et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 2018;29(8):1658–86.
12. Румянцев А. А., Волкова М. И., Гладков О. А., Матвеев В. Б., Проценко С. А., Трякин А. А. и соавт. Практические рекомендации по лечению герминогенных опухолей у мужчин. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023 (том 13), #3s2, стр. 661–694.
13. Gilligan T., Lin D.W., Aggarwal R., et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Testicular Cancer. Version 1.2024 — March 15, 2024. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf.
14. International Collaboration On Cancer Reporting (ICCR). Neoplasia of the testis – orchidectomy histopathology reporting guide. Available at: http://www.iccr-cancer.org/getattachment/Datasets/Published-Datasets/Urinary-Male-Genital/Neoplasia-of-the-Testis-Orchidectomy-TNM8/Testis-Orchidectomy-bookmarked-1st-edition-FINAL-FOR-PUBLICATION.pdf.
15. Tsili A.C., Sofikitis N., Stiliara E., Argyropoulou M.I. MRI of testicular malignancies. . Abdom Radiol (NY) 2019;44(3):1070–82.
16. Hale G.R., Teplitsky S., Truong H. Lymph node imaging in testicular cancer. . Transl Androl Urol 2018;7(5):864–74.
17. Трякин А.А., Федянин М.Ю., Буланов А.А. и др. Метастазы герминогенных опухолей в головной мозг. Опыт Российского онкологического центра. Онкоурология 2013;(4):59–71.
18. Albers P., Göll A., Bierhoff E. et al. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. . Urology 1999;54:714–8.
19. Tabernero J., Paz-Ares L., Salazar R. et al. Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol 2004;171:164–7.
20. Kollmannsberger C., Tandstad T., Bedard P. et al. Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): a large multicenter study. J Clin Oncol 2013;(suppl):4503.
21. De Wit R., Roberts J.T., Wilkinson P.M. et al. Equivalence of three or four cycles of bleomy-cin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized trial of EORTC and MRC. J Clin Oncol 2001;19(6):1629–40.
22. Mead G.M., Cullen M.H., Huddart R. et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with meta-static germ cell cancer: a medical research council trial. Br J Cancer 2005;93:178–84.
23. Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. . J Clin Oncol 1998;16:2500–4.
24. De Wit R., Stoter G., Sleijfer D.T. et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78:828–32.
25. Kollmannsberger C., Beyer J., Liersch R. et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108–14.
26. Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germcell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008;19:448–53.
27. Feldman D.R., Sheinfeld J., Bajorin D.F. et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010;28(10):1706–13. Erratum in: J Clin Oncol 2010;28(34):5126.
28. Hoei-Hansen C.E., Rajpert-De Meyts E., Daugaard G., Skakkebaek N.E. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005;16:863–8.
29. Petersen P.M., Giwercman A., Daugaard G. et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 2002;20:1537–43.
30. Heidenreich A., Höltl W., Albrecht W. et al. Testis-preserving surgery in bilateral testicular germ cell tumours. Br J Urol 1997;79:253–7.
31. Трякин А.А. Лекарственное и комбинированное лечение несеминомных герминогенных опухолей у мужчин. Дис. ... д-ра мед. наук. М., 2015. 254 с.
32. Cohn-Cedermark G., Stahl O., Tandstad T. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors-a review and the SWENOTECA experience. . Andrology 2015;3:102–10.
33. Albers P. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I NSGCT:. AUO trial AH 01/94 by the German Testicular Cancer Study. J Clin Oncol 2008;26(18):2966–72.
34. Fedyanin M, Tryakin A, Bulanov A, et al. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors. J Cancer Res Clin Oncol. 2015 Jul;141(7):1259-64.
35. Tran B., Ruiz-Morales J.M., Billalabeitia E.G. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). Cancer Med. 2019 Nov 12. doi: 10.1002/cam4.2674. [Epub ahead of print].
36. Tryakin A, Fedyanin M, Bulanov A, et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol. 2018 Sep;144(9):1817-1823.
37. Feldman D.R., Lorch A., Kramar A. et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the Global Germ Cell Cancer Group. J Clin Oncol 2016;34(4):345–51.
38. Daneshmand S., Albers P., Fossa S.D. et al. Contemporary management of postchemotherapy testis cancer. EurUrol 2012;62:867–76.
39. Tryakin A., Fedyanin M., Mitin A. et al. Complete disappearance of retroperitoneal lymph nodes after induction chemotherapy in advanced nonseminomatous germ cell tumors (NSGCT): is there a place for adjunctive surgery? J Clin Oncol 2012;30(15 suppl).
40. Kollmannsberger C. et. al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. . J Clin Oncol 2010;28:537.
41. De Santis M., Becherer A., Bokemeyer C. et al. 2-18Fluoro-deoxy-D-glucose positron emis-sion tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034–9.
42. Cathomas R., Klingbiel D., Bernard B. et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol 2018;4:JCO1800210. .
43. Motzer R.J., Sheinfeld J., Mazumdar M. et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18(12):2413–8. .
44. Varuni Kondagunta, Jennifer Bacik, Alessia Donadio,et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005 Sep 20;23(27):6549-55..
45. Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:2500–4.
46. Donadio A.C., Motzer R.J., Bajorin D.F. et al. Chemotherapy for teratoma with malignant transformation. . J Clin Oncol 2003;21(23):4285–91.
47. S., Daneshmand. Role of surgical resection for refractory germ cell tumors. Urol Oncol 2015;33(8):370–8.
58. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92(8):715–27.
59. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016;6(1):e007997.
60. Nicole L Stout, Daniel Santa Mina, Kathleen D Lyons, Karen Robb, Julie K Silver A systematic review of rehabilitation and exercise recommendations in oncology guidelines. CA Cancer J Clin. 2021 Mar;71(2):149-175. doi: 10.3322/caac.21639.
61. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol 2015;22(13):4117–23.
62. Swarm R., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2010;8:1046–86.
63. Azhar R.A., Bochner B., Catto J. et al. Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 2016;70(1):176–87.
64. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016;6(1):e007997.
65. Shin K.Y., Guo Y., Konzen B. et al. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011;90(5):63–8.
66. Shehadeh A., El Dahleh M., Salem A. et al. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome. Hematol Oncol Stem Cell Ther 2013;6(3–4):105–11.
67. Fallon M., Giusti R., Aielli F. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. . Ann Oncol 2018;29(Suppl 4):iv166–91.
68. Cox C.L., Montgomery M., Oeffinger K.C. et al. Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009;115(3):642–54.
69. Musculoskeletal Cancer Surgery. Ed. by M. Malawer. Dordrecht: Springer, 2013. Pp. 583–593.
70. Committee NMA: The diagnosis and treatment of lymphedema. Position Statement of the National Lymphedema Network. 2011. 19 p.
71. Segal R., Zwaal C., Green E. et al. Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. . Curr Oncol 2017;24(4):e290–315.
72. Boyd C., Crawford C., Paat C.F. et al. Evidence for Massage Therapy Working G: The impact of massage therapy on function in pain populations-a systematic review and meta-analysis of randomized controlled trials: Part II, Cancer pain populations. Pain Med 2016;17(8):1553–68.
73. Stout N.L., Baima J., Swisher A.K. et al. A systematic review of exercise systematic reviews in the cancer literature (2005–2017). PM R 2017;9(9S2):S347–84.
74. Fizazi, K., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germcell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol, 2014. 15: 1442.
75. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3(7):961–8.
76. Freeman Jodie, Klingele Anna, Wolf Ursula. Effectiveness of music therapy, aromatherapy, and massage therapy on people in palliative care with end-of-life needs: A systematic review. J Pain Symptom Manage. 2024 Aug 12:S0885-3924(24)00903-5.
77. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44(9):1289–304.
78. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. . Support Care Cancer 2018;26(4):1019–28.
79. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012;30(15 suppl):9019.
80. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. . Bioelectromagnetics 2017;38(2):85–94.
81. Kilinc M., Livanelioglu A., Yildirim S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014;46(5):454–60.
82. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014;9(9):e107418.
83. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018;10(Suppl35):S4391–9.
84. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017;21(2):226–33.
85. Rief H., Omlor G., Akbar M. et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy – first results of a randomized pilot trial. BMC Cancer 2014;14:6.
86. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. . Photomed Laser Surg 2015;33(10):487–91.
87. Temoshok L. Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. Soc Sci Med 1985;20(8):833–40.
88. Solveigh Paola Lingens, Georgia Schilling, Holger Schulz, and Christiane Bleich. Effectiveness of brief psychosocial support for patients with cancer and their relatives: a quasi-experimental evaluation of cancer counselling centres. BMJ Open. 2023; 13(3): e068963.
89. Lichtenthal W.G., Cruess D.G., Schuchter L.M., Ming M.E. Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma. J Health Psychol 2003;8(6):705–19.
90. Sollner W., Zschocke I., Zingg-Schir M. et al. Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 1999;40(3):239–50.
91. Devine D., Parker P.A., Fouladi R.T., Cohen L. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. . Psychooncology 2003;12(5):453–62.
92. Chovanec M., Abu Zaid M., Hanna N. et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 2017;28(11):2670–9.
93. Трякин А.А., Бесова Н.С., Волков Н.М., Гладков О.А., Карасева В.В., Сакаева Д.Д. и соавт. Общие принципы проведения противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023 (том 13), #3s2, стр. 28–41.
94. P Giannatempo, T Greco, L Mariani, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol . 2015 Apr;26(4):657-668. doi: 10.1093/annonc/mdu447.
95. Isamu Tachibana, Sean Q Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol . 2022 Nov 10;40(32):3762-3769. doi: 10.1200/JCO.22.00118
96. Axel Heidenreich, Pia Paffenholz, Florian Hartmann, et al. Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS). Eur Urol Oncol. 2024 Feb;7(1):122-127. doi: 10.1016/j.euo.2023.06.004.
97. Anne Neuenschwander, Chiara Lonati, Luca Antonelli, et al. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus . 2023 May;9(3):541-546. doi: 10.1016/j.euf.2022.11.003.
98. Gordon J Rustin, Graham M Mead, Sally P Stenning, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol . 2007 Apr 10;25(11):1310-5. doi: 10.1200/JCO.2006.08.4889.
99. Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al. Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). J Clin Oncol. 2022 Aug 1;40(22):2468-2478. doi: 10.1200/JCO.21.01199.
100. Andrea Necchi, Nicola Nicolai, Luigi Mariani, et al. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. Clin Genitourin Cancer. 2014 Feb;12(1):63-69.e1. doi: 10.1016/j.clgc.2013.07.005.
101. R T D Oliver, M D Mason, G M Mead, H von der Maase, G J S Rustin, J K Joffe, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005 Jul;366(9482):293-300. doi: 10.1016/S0140-6736(05)66984-X.
102. Meghan Mastrangelo. Cisplatin-Based Therapy and CINV: Optimal Antiemetics During Germ Cell Testicular Cancer Treatment. CJON 2018, 22(2), E31-E36. DOI: 10.1188/18.CJON.E31-E36
103. Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev, 2021 Nov 16;11(11):CD012775
104. Владимирова Л.Ю., Гладков О.А., Королева И.А., Румянцев А.А., Семиглазова Т.Ю., Трякин А.А., Кутукова С.И., Овчинникова Е.Г., Новикова О.Ю., Корниецкая А.Л. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=nausea_vomiting
105. Chaoyang Chen, Ruoming Li, Ting Yang. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. Clinical Therapeutics 2020, 42(8): 1494–1507.e1.
106. Багрова С.Г., Басин Е.М., Борзов К.А., Бычкова Н.М., Деньгина Н. В., Копп М.В., Крылов В.В., Кочетова Т.Ю., Семиглазова Т.Ю. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Практические рекомендации RUSSCO, часть 2.
https://rosoncoweb.ru/standarts/?chapter=bone_pathology
107. Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E,et al.. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy Eur Urol Focus. 2021 Sep;7(5):1130-1136. doi: 10.1016/j.euf.2020.09.017.
108. Chinthaka B Samaranayake, James Anderson, Colm McCabe, Syeda Farah Zahir, John W Upham, Gregory Keir, Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis, Intern Med J,2022 Feb;52(2):272-281.
109. William Knoll, Nathan Fergusson, Victoria Ivankovic , Tzu-Fei Wang, Lucia Caiano, Rebecca Auer, Marc Carrier, Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature, Thromb Res, 2021 Aug:204:114-122.
110. Сомонова О.В., Антух Э.А., Варданян А.В., Громова Е.Г., Долгушин Б.И., Елизарова А.Л., Сакаева Д.Д., Сельчук В.Ю., Трякин А.А., Черкасов В.А. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=thromboembolism
111. NCCN Guidelines. Prevention and Treatment of Cancer-Related Infections. v.1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.
112. Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015 Apr;23(4):1137–43.
113. Mical Paul, Dafna Yahav, Abigail Fraser, Leonard Leibovici. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, Volume 57, Issue 2, February 2006, Pages 176–189.
114. Сакаева Д.Д., Борисов К.Е., Булавина И.С., Когония Л.М., Курмуков И.А., Орлова Р.В., Шабаева М.М. Практические рекомендации по диагностике и лечению фебрильной нейтропении. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=febrile_neutropenia
115. B Vincenzi, A Russo, A Terenzio, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol 2018 Oct;130:70–77.
116. Devika Remash, David S Prince, Catriona McKenzie, et al. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 2021 Aug 28;27(32):5376–5391.
117. Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Практические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=hepatotoxicity
118. Zhujun Mao, Keping Shen, Limin Zhu, et al. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials. Oncol Res Treat 2019;42(7-8):405–413.
119. Albakri, Aref. Systolic heart failure: A review of clinical status and metaanalysis of diagnosis and clinical management methods. Trends in Res, 2018, 1(4), doi: 10.15761/TR.1000124.
120. Jasper Tromp, Wouter Ouwerkerk, Dirk J. van Veldhuisen, et al. A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol HF. Dec 08, 2021.
121. Kashif Kalam, Thomas H.Marwick. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer 2013 Sep;49(13):2900–9.
122. Виценя М.В., Агеев Ф. Т., Орлова Р. В., Полтавская М.Г., Потиевская В.И. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2 https://rosoncoweb.ru/standarts/?chapter=cardiovascular_toxicity
123. Jing Li, Hengxiu Yan. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol 2018 Oct;82(4):571–583.
124. Королева И.А., Болотина Л.В., Гладков О.А., Горбунова В.А., Когония Л.М., Круглова Л.С., Орлова Е.В., Орлова Р.В. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=dermatological_reactions
125. Emily J Martin, Andrew R Bruggeman, Vinit V Nalawade, et al. Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer. J Natl Compr Canc Netw 2020 May;18(5):569–574.
126. M A E de van der Schueren, A Laviano, H Blanchard, et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol. 2018 May; 29(5): 1141–1153.
127. Сытов А.В., Зузов С.А., Кукош М.Ю., Лейдерман И.Н., Обухова О.А., Потапов А.Л., Хотеев А.Ж. Практические рекомендации по нутритивной поддержке онкологических больных. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=nutritional_support
128. Perazella, Mark A. Onco-Nephrology. Renal Toxicities of Chemotherapeutic Agents
Clinical Journal of the American Society of Nephrology, 2012 October, 7(10):p 1713-1721.
129. Han Li, Jinsheng Xu, Yaling Bai, Shenglei Zhang, Meijuan Cheng, Jingjing Jin. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investigational New Drugs, 2021, Volume 39, pages 860–870.
130. Songtao Li, Xiuyun He, Linjie Ruan, Ting Ye, Yulong Wen, Zhihua Song, Siying Hu, Yu Chen, Bo Peng, Shijie Li. Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11, Published online 2021 Dec 16.
131. Громова Е.Г., Бирюкова Л.С., Джумабаева Б.Т., Курмуков И.А. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=nephrotoxicity
132. NCCN guidelines. Management of Immunotherapy-Related Toxicities. Version 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.
133. Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. Journal for ImmunoTherapy of Cancer, 2018, article number: 103.
134. Guillermo De Velasco, Youjin Je, Dominick Bossé, Mark M. Awad, Patrick A. Ott, Raphael B. Moreira, Fabio Schutz, Joaquim Bellmunt, Guru P. Sonpavde, F. Stephen Hodi, Toni K. Choueiri. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res, 2017, 5 (4): 312–318
135. Hongchuan Zhang MD, Xuemei Li MD, Xingliang Huang MD, Junfeng Li MD, Hong Ma MD, Rui Zeng MD, Impact of corticosteroid use on outcomes of non–small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, Volume 46, Issue4, August 2021, Pages 927-935
136. Проценко С.А., Баллюзек М.Ф., Васильев Д.А., Жукова Н.В., Новик А.В., Носов Д.А., Петенко Н.Н., Семенова А.И., Харкевич Г.Ю., Юдин Д.И. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=immunerelated_adverse_events
137. P.Bossi, A.Antonuzzo, N.I.Cherny, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 2018, 29(4): pages iv126-iv142.
138. D. E. Peterson, R.-J. Bensadoun, F. Roila. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology 21 (Supplement 5): v261–v265, 2010.
139. Семиглазова Т.Ю., Беляк Н.П., Владимирова Л.Ю., Корниецкая А.Л., Королева И.А., Нечаева М.Н., Раджабова З.А., Телетаева Г.М., Ткаченко Е.В. Практические рекомендации по лечению и профилактике мукозитов. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=mucositis
140. Yasuo Ohashi, Yukari Uemura, Yasuhito Fujisaka, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 2013 Apr;104(4):481–5.
141. Anat Gafter-Gvili 1, Benaya Rozen-Zvi, Liat Vidal, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia — systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013 Jan;52(1):18–29.
142. Орлова Р.В., Гладков О.А., Кутукова С.И., Копп М.В., Королева И.А., Ларионова В.Б., Моисеенко В.М., Поддубная И.В., Птушкин В.В. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации RUSSCO, часть 2.
https://rosoncoweb.ru/standarts/?chapter=anemia
143. Fangyuan Zhang, Aomei Shen, Yinghui Jin, Wanmin Qiang. The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews. BMC Complement Altern Med. 2018; 18: 236.
144. Сытов А.В., Зузов С.А., Кукош М.Ю., Лейдерман И.Н., Потапов А.Л., Хотеев А.Ж. Практические рекомендации по лечению синдрома анорексии-кахексии у онкологических больных. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=anorexia-cachexia
145. Marcus Yeow, Shauna Soh, Ryan Yap, Serene Si Ning Goh, Charleen Shanwen Yeo, Zhiwen Joseph Lo. A systematic review and network meta-analysis of randomized controlled trials on choice of central venous access device for delivery of chemotherapy. Journal of Vascular Surgery_ Venous and limphatic disorders. V 10, issue 4, p 1184-1191
146. Исянгулова А.З., Шин А.Р., Петкау В.В. Центральный венозный доступ. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=central_venous_access
147. Firas Y Kreidieh, Hiba A Moukadem, and Nagi S El Saghir
Overview, prevention and management of chemotherapy extravasation
World J Clin Oncol. 2016 Feb 10; 7(1): 87–97.
148. Буйденок Ю.В., Обухова О.А. Рекомендации по профилактике и лечению последствий экстравазации противоопухолевых препаратов. Практические рекомендации RUSSCO,
часть 2. https://rosoncoweb.ru/standarts/?chapter=extravasation_antitumor_drugs
149. Margaux Evenepoel, Vincent Haenen, Tom De Baerdemaecker, Mira Meeus, Nele Devoogdt, Lore Dams, Sophie Van Dijck, Elien Van der Gucht, An De Groef. Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis. Pain Symptom Manage, 2022 Mar;63(3):e317-e335
150. Когония Л.М., Новиков Г.А., Орлова Р.В., Сидоров А.В., Королева И.А., Сакаева Д.Д.
Практические рекомендации по лечению хронического болевого синдрома у взрослых онкологических больных. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=chronic_pain_syndrome
151. S. Rosello, I. Blasco, L. Garcıa Fabregat, A. Cervantes, K. Jordan. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Annals of Oncology 28 (Supplement 4): iv100–iv118, 2017
152. Орлова Р.В., Жабина А.С., Иванова А.К., Наталенко К.Е., Телетаева Г.М. Практические рекомендации по лечению инфузионных реакций при проведении противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2.
https://rosoncoweb.ru/standarts/?chapter=infusion_reactions
153. Jessica P Hwang, Andy S Artz, Parth Shah, Banu Symington, Jordan J Feld, et al. Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO Oncol Pract 2022 Sep;18(9):636-644. doi: 10.1200/OP.22.00074.
154. Феоктистова П.С., Винницкая Е.В., Нурмухаметова Е.А., Тихонов И.Н. Практические рекомендации по профилактике и лечению реактивации/обострения хронических вирусных гепатитов у пациентов, получающих противоопухолевую терапию. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=chronic_viral_hepatitis
155. Paola Alberti, Alessandro Salvalaggio, Andreas A. Argyriou, Jordi Bruna, Andrea Visentin, Guido Cavaletti, and Chiara Briani. Neurological Complications of Conventional and Novel Anticancer Treatments. Cancers (Basel). 2022 Dec; 14(24): 6088.
156. Латипова Д.Х., Андреев В.В., Маслова Д.А., Новик А.В., Проценко С.А. Неврологические осложнения противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=neurological_complication
157. Y. Andreu, A. Soto-Rubio, M. Ramos-Campos, A. Escriche-Saura, M. Martínez, and J. Gavilá. Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors. Scientific Reports, 2022; 12: 18673.
158. E D Kreuser, W D Hetzel, D O Billia, E Thiel. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev. 1990 Sep;17(2-3):169-75. doi: 10.1016/0305-7372(90)90043-f.
159. Стенина М.Б., Протасова А.Э., Самушия М.А., Юренева С.В. Практические рекомендации по коррекции гормоноопосредованных побочных явлений противоопухолевой терапии. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=hormone-mediated_side_events58. Walsh JS, Marshall H, Smith IL, et al. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med. 2019;16(11):1-18. doi:10.1371/journal.pmed.1002960